オプションチェーンは、Jiuzi Hldgsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Jiuzi Hldgsの市場センチメントを評価します。.

Jiuzi Hldgs (NASDAQ:JZXN) 株価情報, オプションチェーン

Jiuzi Hldgs

Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.

Jiuzi Holdings Inc

Castor Maritime Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRM#NASDAQ">CTRM</a>), ("Castor" or the "Company"), a diversified global shipping company, announces that on December 12, 2024, it entered, through a wholly owned subsidiary, into an Share Purchase Agreement ("SPA") with MPC Münchmeyer Petersen &amp; Co. GmbH ("MPC Holding") for the acquisition of 26,116,378 shares representing 74.09% of the shares of the Frankfurt-listed investment and asset manager MPC Münchmeyer Petersen Capital AG (Deutsche Börse, Scale, ISIN DE000A1TNWJ4) ("MPC Capital").
The acquisition price of the shares has been agreed at a price of €7.00 per share, which is equal to an aggregate cost of €182.8 million payable in cash (approx. USD 192.6 million equivalent), excluding any transaction-related costs. As part of the transaction Castor secured a $100,000,000 new senior term loan facility and $50,000,000 proceeds from the issuance of 50,000 additional Series D cumulative convertible preferred shares, both from Toro Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TORO#NASDAQ">TORO</a>), ("Toro"), an entity controlled by Petros Panagiotidis, Castor's Chairman and CEO.

CTRM

TORO

Castor Maritime Enters Into An Share Purchase Agreement With MPC Münchmeyer Petersen & Co. GmbH For The Acquisition Of 26,116,378 Shares Representing 74.09% Of The Shares For ~$192.6M

On Thursday, Keros Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial Phase 2 trial of cibotercept (KER-012) in combination with background therapy in pulmonary <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42456129/keros-therapeutics-announces-update-on-the-phase-2-tropos-trial" rel="noreferrer noopener">arterial hypertension patients</a>.
The move is based on a safety review, as the trial unanticipatedly observed adverse pericardial effusion events.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42297870/keros-therapeutics-licensing-deal-with-takeda-aligns-with-broader-opportunity-for-elritercept-analyst" rel="noreferrer noopener">Keros Therapeutics&#8217; Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst</a>
Pericardial effusion is&nbsp;when too much fluid builds up in the sac around the heart, called the pericardium.&nbsp;This fluid can pressure the heart, making it difficult to function properly.
The TROPOS trial is fully enrolled, and dosing in the 1.5 mg/kg treatment arm remains ongoing following completion of a risk and benefit assessment of the data from the ongoing trial that was conducted by the independent Data Monitoring Committee (DMC) followed by a select group of unblinded individuals at Keros.
The decision to halt the dosing in 3.0 mg/kg and 4.5 mg/kg treatment arms and continue dosing in the 1.5 mg/kg treatment arm was made in consultation with the independent DMC for the trial.
The company intends to continue ongoing safety and efficacy data collection for all treatment arms in the trial.
The company continues to expect to present topline data from all treatment arms in this trial in the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40684511/keros-therapeutics-announces-update-on-enrollment-in-the-phase-2-tropos-trial" rel="noreferrer noopener">second quarter of 2025</a>.
Price Action: KROS stock is down 74.1% at $17.80&nbsp;during the premarket session at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42457904/tat-technologies-secures-17-million-mro-deal-with-major-cargo-carrier-to-repair-apus-for-boeing-757-and-767-aircraft" target="_blank" rel="noreferrer noopener">TAT Technologies Secures $17 Million MRO Deal With Major Cargo Carrier: Details</a></li>
</ul>

Biotech

News

Health Care

Movers

Trading Ideas

General

KROS

Keros Therapeutics Loses 75% Value In A Single Session - Here's Why

JMP Securities analyst Silvan Tuerkcan reiterates Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Market Outperform and maintains $21 price target.

Price Target

Reiteration

Analyst Ratings

RLAY

JMP Securities Reiterates Market Outperform on Relay Therapeutics, Maintains $21 Price Target

COHN

Cohen & Company Acquires Tax & Wealth Management; Terms Not Disclosed

<ul>
<li>Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery</li>
<li>Factors supporting the go-ahead for the 212-person registration study in the target population include:
<ul>
<li>Multikine led to significant rates of tumor regression</li>
<li>Pre-surgical tumor regressions were confirmed at surgery and forecast survival benefit</li>
<li>Target population is likely to show significant survival prolongation in the confirmatory study</li>
</ul>
</li>
<li>Confirmatory study target population selection is based on:
<ul>
<li>Strong statistical significance in a large subgroup of 114 patients</li>
<li>Subgroup analysis was pre-defined in the statistical analysis plan (SAP)</li>
<li>Strong biological rationale for the results based on Multikine's mechanism of action (MOA)</li>
</ul>
</li>
</ul>
CEL-SCI Corporation (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today highlights strong biological rationale for the use of Multikine in the confirmatory registration head and neck cancer study. This study of 212 newly diagnosed locally advanced, resectable head and neck cancer patients was given the go-ahead as a confirmatory registration study by FDA and will focus on those patients who showed a 73% survival with Multikine vs. a 45% for the control patients not treated with Multikine in the prior Phase 3 study.

CEL-SCI Announced Multikine Demonstrates Tumor Regression Pre-Surgery In 3 Weeks; FDA Approves 212-Person Study With 73% Survival Rate Vs. 45% Control In Head And Neck Cancer

JMP Securities analyst Chris Muller maintains Ready Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RC#NYSE">RC</a>) with a Market Outperform and lowers the price target from $10.5 to $9.5.

JMP Securities Maintains Market Outperform on Ready Capital, Lowers Price Target to $9.5

JP Morgan analyst Bryan Smilek maintains Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) with a Overweight and raises the price target from $360 to $400.

DUOL

JP Morgan Maintains Overweight on Duolingo, Raises Price Target to $400

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4323650-1&amp;h=1847303498&amp;u=http%3A%2F%2Fwww.zynex.com%2F&amp;a=Zynex%2C+Inc">Zynex, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) ("Zynex", "ZMS", "we" or the "Company"),&nbsp;an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced highlights from a recent study comparing its NiCO&#x2122; laser pulse oximeter to conventional LED pulse oximeters for the effects of skin pigmentation on SpO2 measurements conducted by the University of California, San Francisco (UCSF) Hypoxia Lab.
Zynex's NiCO pulse oximeter utilizes highly precise laser technology to measure blood oxygenation levels directly, as opposed to current pulse oximeter products, which only estimate oxygenation levels using an LED-based technology. LED pulse oximeters have been shown to mismeasure oxygen levels in several populations, most prominently in individuals with darker skin pigmentation.
A poster presentation for the study was recently accepted and presented at the ANESTHESIOLOGY 2024 Event hosted by the American Society of Anesthesiologists that took place October 18 - 22 in Philadelphia. The presentation titled, "Laser-Based Pulse Oximetry Eliminates Effects of Skin Pigmentation on SpO2 Measurements," included results from a study conducted under the supervision of Dr. Philip Bickler at the UCSF Hypoxia Lab.
Nine darkly pigmented and nine lightly pigmented participants were recruited for this controlled desaturation study. Four NiCO pulse oximeters and two different commercially available LED-based pulse oximeters were used on each participant. Conclusions from the study showed the NiCO pulse oximeter did not demonstrate a bias for dark pigmented participants compared to lightly pigmented participants. By comparison, conventional LED-based pulse oximeters in the present study read falsely higher on darkly pigmented participants, specifically at lower oxygen saturation levels.

ZYXI

Zynex Announces Highlights From A Recent Study Comparing Its NiCo Laser Pulse Oximeter To Conventional LED Pulse Oximeters For The Effects Of Skin Pigmentation On SpO2 Measurements Conducted By The University Of California, San Francisco Hypoxia Lab

<ul>
<li>TSLA</li>
<li>NVDA</li>
<li>ACHR</li>
<li>GOOGL</li>
<li>GOOG</li>
<li>AMD</li>
<li>ADBE</li>
<li>AAPL</li>
<li>MSTR</li>
<li>INTC</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

ACHR

ADBE

GOOG

GOOGL

INTC

MSTR

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of December 12, 2024 (Via Swaggy Stocks)

WIIM

AYRO

AYRO shares are trading higher after the company announced it has been named a Tier One supplier for General Motors through its partnership with GLV Ventures.

Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 <a href="https://clinicaltrials.gov/study/NCT04538625">OnTarget</a> trial evaluating crofelemer for prophylaxis of CTD
The majority of patients in the OnTarget placebo group on abemaciclib and pertuzumab-based therapies required dose reduction or elimination
SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2024 / <a href="https://pr.report/4u8b">Jaguar Health, Inc.</a> <a href="https://pr.report/4yse">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar") family company <a href="https://pr.report/4u8d">Napo Pharmaceuticals</a> ("Napo") today provided an overview of the data from the poster presentation conducted yesterday, December 11, 2024, at the <a href="https://pr.report/4u8e">San Antonio Breast Cancer Symposium</a> (SABCS) about the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the Phase 3 <a href="https://pr.report/4u8f">OnTarget</a> trial, which indicates that crofelemer achieved statistically significant results in this subgroup. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy.

JAGX

Jaguar Health's Napo Pharmaceuticals Reports Crofelemer Shows Statistically Significant Results In Phase 3 OnTarget Trial For Breast Cancer Patients

JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Market Outperform and maintains $8 price target.

PRQR

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target

RIOT

Riot shares are trading higher following a report from The Wall Street Journal indicating activist investor Starboard Value has taken a stake in the company.

In the latest episode of Galaxy Research&#8216;s "Galaxy Brains" podcast, MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) executive chairman Michael Saylor reflected on Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) historic rise to $100,000 and what it means for the <a href="https://www.benzinga.com/digital-assets">future of digital assets.</a>
What Happened: Calling it a "numeric punctuation" and predicting that &#8220;it will be embraced,&#8221; Saylor framed the milestone as proof of Bitcoin's permanence and its maturation into a cornerstone of the financial landscape. 
He believes Bitcoin is not just a part of the future financial landscape—it is actively shaping it.
In the podcast <a href="https://www.youtube.com/watch?v=R87vco0jHvo">released</a> on Wednesday, Saylor described this moment as signalling Bitcoin's transition from a speculative asset to an institutional mainstay. 
"Bitcoin is here to stay," Saylor declared, emphasizing that it is no longer just part of the financial future but actively shaping it.
Saylor outlined his vision for Bitcoin's role in national economies, advocating for the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41902155/bitcoin-to-augment-gold-as-the-next-strategic-reserve-asset-says-expert">replacement of gold reserves</a> with Bitcoin.
He suggested that such a shift could radically alter global financial dynamics, <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42345293/bitcoin-is-global-capital-says-michael-saylor-every-nation-that-respects-property-rights-is-going-to-support-btc">strengthening nations</a> that adopt this strategy.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42429413/goldman-sachs-ceo-says-bank-can-consider-bitcoin-ethereum-spot-trading-if-regulations-allow">Goldman Sachs CEO Says Bank Can Consider Bitcoin, Ethereum Spot Trading If Regulations Allow</a>
Why It Matters: Saylor also recounted MicroStrategy's journey, navigating volatile markets and regulatory challenges, including China's crypto crackdown. 
Bitcoin has bolstered <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42433049/microstrategy-nasdaq-100-inclusion-on-the-horizon-could-spell-59-upside-says-bernstein">MicroStrategy's performance</a>, with its stock outperforming major tech companies and Bitcoin itself since implementing its Bitcoin-focused strategy.
Saylor attributes this success to MicroStrategy&#8217;s unique &#8220;2121 plan,&#8221; a $21 billion equity shelf registration and $21 billion fixed income plan over three years, which he calls &#8220;the biggest equity shelf registration in the history of capital markets.&#8221;
Saylor was critical of companies allocating small portions, such as 2% of their portfolios to Bitcoin, calling it "silly." 
He argued for substantial Bitcoin holdings as a superior alternative to conventional cash management strategies like dividends or stock buybacks.
Saylor predicted that if giants like Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) adopted a Bitcoin strategy akin to MicroStrategy&#8217;s, their market caps could see significant growth.
What's Next: Saylor's remarks highlight Bitcoin's potential as a transformative asset, acting not only a hedge against inflation but also a strategic tool for <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42413650/michael-saylor-urges-us-to-ditch-gold-for-bitcoin-sell-the-past-own-the-future">economic and financial innovation.</a>
Read Next:
<ul>
<li><a href="https://finance.yahoo.com/news/heres-much-100-bitcoin-could-190038492.html">Here&#8217;s How Much $100 In Bitcoin Could Be Worth In 2030 If Cathie Wood&#8217;s Price Target Is Reached</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSFT

Michael Saylor Lauds Bitcoin's $100,000 Milestone: 'It Will Be Embraced' By The World's Wealthy And Powerful

<a href="https://www.wsj.com/finance/currencies/activist-starboard-value-takes-stake-in-bitcoin-mining-company-riot-82b3796f?mod=latest_headlines" title="https://www.wsj.com/finance/currencies/activist-starboard-value-takes-stake-in-bitcoin-mining-company-riot-82b3796f?mod=latest_headlines">https://www.wsj.com/finance/currencies/activist-starboard-value-takes-stake-in-bitcoin-mining-company-riot-82b3796f?mod=latest_headlines</a>

'Activist Starboard Value Takes Stake In Bitcoin-Mining Company Riot; Starboard Wants Riot To Convert Some Of Its Bitcoin-Mining Facilities Into Space For Big Data-Center Users' - WSJ

AYRO Has Been Named A Tier One Supplier For GM Through Its Partnership With GLV Ventures

JP Morgan analyst David Karnovsky maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Overweight and raises the price target from $137 to $150.

JP Morgan Maintains Overweight on Live Nation Entertainment, Raises Price Target to $150

Devoted pet lovers across Canada can now get pet supplies delivered directly to their doorstep from Canada's leading pet retailer
SAN FRANCISCO and MARKHAM, ON, Dec. 12, 2024 /PRNewswire/ -- Instacart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>), the leading grocery technology company in North America, and Pet Valu (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PET#TSX">PET</a>), the leading specialty retailer of pet food and pet-related supplies in Canada, today announced that devoted pet lovers can now shop over 600 locations across the country exclusively on Instacart for same-day delivery in as fast as an hour. This collaboration will make shopping for pet essentials easier and more convenient than ever before, with quick and reliable delivery straight to customers' homes.

CART

TSX:PET

Pet Valu Expands Canadian Pawprint On Instacart, Users Can Now Shop Over 600 Locations Across The Country Exclusively On Instacart For Same-Day Delivery In As Fast As An Hour

Blink Charging Co.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) subsidiary Blink Charging UK secured a three-year contract to install, maintain, and manage 41 electric vehicle (EV) chargers and 21 contactless payment terminals at Kings College NHS Trust&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42457243/kings-college-nhs-trust-selects-blink-charging-to-install-41-ev-chargers-at-orpingtons-princess-ro" rel="noreferrer noopener">flagship Princess Royal University Hospital</a>.
Starting in May 2025, patients, visitors, and staff will have access to fast and convenient EV charging, along with seamless payments through the contactless terminals.
In the first phase of the project, Blink UK will install 41 new vehicle-to-grid EV chargers at the hospital, with 35 on the ground floor and six on the first floor.
The chargers are part of a new generation designed to enhance EV charging infrastructure efficiency.
Additionally, 21 contactless payment terminals will be set up throughout the car park and surrounding areas for convenient, hassle-free payments.
Over the three-year project, additional EV chargers will be installed at other sites across the King&#8217;s College NHS Trust estate.
This installation is part of King&#8217;s Green Plan, which aims to reduce the Trust&#8217;s environmental impact through initiatives such as climate-conscious building adaptations and sustainable travel options for patients, visitors, and staff.
The plan aligns with the broader Greener NHS vision to deliver a Net Zero health service.
Yesterday, the company stated that it is making significant strides in supporting the transition to greener transportation with its ongoing&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42444170/whats-going-on-with-blink-charging-stock-today" rel="noreferrer noopener">collaboration with Norfolk County Council</a>.
By February 2025, Blink Charging will add 22 new charging stations at 12 locations, bringing the total number of charging stations to 46 in Norwich.
Price Action: BLNK shares are up 0.60% at $1.69 premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42458637" target="_blank" rel="noreferrer noopener">Nvidia Refutes Claims Of Reducing Supplies To China Amid Antitrust Investigation</a></li>
</ul>

Equities

Contracts

Small Cap

BLNK

Blink UK To Install 41 EV Chargers At Princess Royal Hospital: Details

National Nuclear Security Agency sponsors Rubrik's authorization as the company showcases its ability to deliver data security and cyber resilience
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rubrik.com%2F&amp;esheet=54165756&amp;newsitemid=20241212948894&amp;lan=en-US&amp;anchor=Rubrik&amp;index=1&amp;md5=ed6ac47dcfd9a25da19f300ae14c279a">Rubrik</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>), the Zero Trust Data Security&#x2122; Company, today announces <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.rubrik.com%2Findustries%2Ffederal-government&amp;esheet=54165756&amp;newsitemid=20241212948894&amp;lan=en-US&amp;anchor=Rubrik+Security+Cloud+%26%238211%3B+Government&amp;index=2&amp;md5=3cc6ad367a8e2b27346222eafc54e35b">Rubrik Security Cloud – Government</a> has received Federal Risk and Authorization Management Program (FedRAMP&#xAE;) authorization at the Moderate Impact Level. Rubrik Security Cloud – Government, built on zero trust architecture, secures enterprise, cloud, and SaaS data to ensure mission continuity in the wake of cyberattacks. The National Nuclear Security Administration (NNSA), an Office of the U.S. Department of Energy, served as the agency sponsor for Rubrik's FedRAMP authorization.
FedRAMP is a government-wide program which provides a standardized approach to security assessment, authorization, and continuous monitoring of cloud products and services. FedRAMP helps to accelerate the adoption of secure, modern cloud technologies for federal agencies, with emphasis on the security and protection of federal information. FedRAMP Moderate Impact Level authorization is most appropriate for government agencies where the "loss of confidentiality, integrity, and availability would result in serious adverse effect on an agency's operations, assets, or individuals," according to FedRAMP.

RBRK

Rubrik Security Cloud Government Achieves FedRAMP Authorization

Jiuzi Holdings enters into non-binding LOI for Shenzhen Maigesong acquisition

LE and DOGZ among Consumer Discretionary movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We&rsquo;re diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning!



Moving stocks this morning are strong early morning trading, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>HWH International (NASDAQ:<a href="https://investorplace.com/stock-quotes/hwh-stock-quote/">HWH</a>) stock is rocketing more than 85% with strong early morning trading.</li>



<li>Zhongchao (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcmd-stock-quote/">ZCMD</a>) shares are soaring over 50% with heavy pre-market trading.</li>



<li>Hub Cyber Security (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/">HUBC</a>) stock is surging more than 30% with increasing trading activity on Thursday morning.</li>



<li>Brooge Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/brog-stock-quote/">BROG</a>) shares are rising over 21% as it also experiences strong trading today.</li>



<li>A.k.a. Brands (NYSE:<a href="https://investorplace.com/stock-quotes/aka-stock-quote/">AKA</a>) stock is increasing 17% without any clear news this morning.</li>



<li>Orgenesis (NASDAQ:<a href="https://investorplace.com/stock-quotes/orgs-stock-quote/">ORGS</a>) shares are gaining more than 16% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318209149&amp;type=PDF&amp;symbol=ORGS&amp;cdn=778bdb482c018a07a4dec09546e61eb2&amp;companyName=Orgenesis+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-04-02">following recent insider buying</a>.</li>



<li>Candel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cadl-stock-quote/">CADL</a>) stock is climbing over 15% despite a lack of news on Thursday.</li>



<li>AngioDynamics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ango-stock-quote/">ANGO</a>) shares are jumping more than 15% after releasing its <a href="https://www.nasdaq.com/press-release/angiodynamics-reports-fiscal-year-2024-third-quarter-financial-results-updates-fiscal">fiscal Q3 2024 earnings report</a>.</li>



<li>Addex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/">ADXN</a>) stock is getting an over 14% boost as it continues to rally on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318212492&amp;type=PDF&amp;symbol=ADXN&amp;cdn=b99f04f9c986cd5ad74a2038763835fe&amp;companyName=Addex+Therapeutics+Ltd&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-04-03">neurological company launch</a>.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) shares are up more than 13% without any clear news to report.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Casa Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/casa-stock-quote/">CASA</a>) stock is plummeting over 31% after <a href="https://www.nasdaq.com/press-release/casa-systems-initiates-court-supervised-chapter-11-sale-process-for-businesses-2024">filing for bankruptcy</a>.</li>



<li>View (NASDAQ:<a href="https://investorplace.com/stock-quotes/view-stock-quote/">VIEW</a>) stock is diving more than 29% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318216587&amp;type=PDF&amp;symbol=VIEW&amp;cdn=229f694a9f04258b182e980a2525d125&amp;companyName=View+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-04">alongside a delisting notice</a>.</li>



<li>Globavend (NASDAQ:<a href="https://investorplace.com/stock-quotes/gvh-stock-quote/">GVH</a>) shares are tumbling over 27% on Thursday morning.</li>



<li>Flora Growth (NASDAQ:<a href="https://investorplace.com/stock-quotes/flgc-stock-quote/">FLGC</a>) stock is taking a more than 20% beating after <a href="https://finance.yahoo.com/news/flora-growth-corp-announces-launch-003700210.html">launching a share offering</a>.</li>



<li>Achilles Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/achl-stock-quote/">ACHL</a>) shares are sliding over 19% alongside its <a href="https://www.nasdaq.com/press-release/achilles-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-and">Q4 2023 earnings report</a>.</li>



<li>XTI Aerospace (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtia-stock-quote/">XTIA</a>) stock is decreasing more than 14% <a href="https://investorplace.com/2024/04/why-is-xti-aerospace-xtia-stock-up-89-today/">after rallying yesterday</a>.</li>



<li>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) shares are declining over 13% ahead of its <a href="https://www.nasdaq.com/press-release/reliance-global-group-schedules-fourth-quarter-2023-financial-results-and-business">Q4 conference call</a>.</li>



<li>Jiuzi (NASDAQ:<a href="https://investorplace.com/stock-quotes/jzxn-stock-quote/">JZXN</a>) stock is slipping more than 13% as it continues to fall <a href="https://www.nasdaq.com/press-release/jiuzi-holdings-enters-into-a-non-binding-loi-for-the-acquisition-of-shenzhen">on acquisition plans</a>.</li>



<li>Digital Health Acqsuitiion (NASDAQ:<a href="https://investorplace.com/stock-quotes/dhac-stock-quote/">DHAC</a>) shares are dipping over 13% without any apparent news.</li>



<li>Telesis Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/tbio-stock-quote/">TBIO</a>) stock closes out our pre-market stock movers down more than 11%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-april-4th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

EC, ABAT and BORR among pre-market losers

Jiuzi Holdings received Nasdaq notification letters

Jiuzi Holdings announces 1-for-13 reverse share split

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings, Inc. has finalized an employment agreement with Huijie Gao, appointing him as Chief F...

Jiuzi Holdings Announces New CFO and Employment Terms

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings, Inc. reports a substantial increase in total assets, from $11.39 million to $56.22 mi...

Jiuzi Holdings Reports Surge in Total Assets

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings, Inc. has entered into a share purchase agreement to sell all of its 100% equity inter...

Jiuzi Holdings Announces Major Equity Sale

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings Inc. has entered into a Securities Purchase Agreement to sell 500,000 ordinary shares ...

Jiuzi Holdings Sells Shares to International Investors

ABAT

ABIO

ACHL

ADXN

ANGO

AUVI

BORR

BROG

CADL

CASA

DHAC

DOGZ

DXYZ

EGOX

FLGC

GCTS

HSDT

HUBC

JZXN

KYCH

LGVC

LIFW

MAMO

ONMD

ORGS

RELI

REPX

TBIO

ULTA

VIEW

XTIA

ZCMD

Press Releases

Jiuzi Holdings Received Nasdaq Notification Letter Related to Late Filing of Annual Report on Form 20-F

Jiuzi Holdings Enters into a Non-Binding LOI for the Acquisition of Shenzhen Maigesong

Jiuzi Holdings Received Nasdaq Notification Letters

Jiuzi Holdings Inc. Announces 1-For-13 Reverse Share Split

Jiuzi Holdings and Shenzhen Maigesong Terminate Negotiations to Focus on Future Growth

Autozi Internet Technology (Global) Ltd. - Class A Ordinary Shares

Autozi Internet Tech

Cango Inc. American Depositary Shares, each representing two (2) Class A Ordinary Shares

Comments

Jiuzi Hldgs

Jiuzi Hldgs (JZXN) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル